CHA2DS2-VASc v.1
Risk stratification for stroke based on the CHA2DS2-VASc score defined by the European Society of Cardiology (ESC) guidelines for management of atrial fibrillation. The result is interpreted as 0p - low risk, 1p - intermediate risk, 2p or more - high risk. For specific risk rates, please view model description or reference [4].
To record an individual's CHA2DS2-VASc score parameters and total score.
Use for stroke risk stratification in patients with atrial fibrillation. CHA2DS2-VASc is an acronym, with each factor contributing points to the total score: - Congestive heart failure 1p - Hypertension 1p - Age ≥75 years 2p - Diabetes1p - Stroke 2p - Vascular disease 1p - Age 65–74 years 1p - Sex category 1p for female The maximum score is 9p and the result is interpreted as; 0p - low risk 1p - intermediate risk 2p or more - high risk Further interpretation in accordance with [4] 1p - stroke risk 0,6% per year, risk of stroke/TIA/thromboembolism 0,9% per year 2p - stroke risk 2,2% per year, risk of stroke/TIA/thromboembolism 2,9% per year 3p - stroke risk 3,2% per year, risk of stroke/TIA/thromboembolism 4,6% per year 4p - stroke risk 4,8% per year, risk of stroke/TIA/thromboembolism 6,7% per year 5p - stroke risk 7,2% per year, risk of stroke/TIA/thromboembolism 10,0% per year 6p - stroke risk 9,7% per year, risk of stroke/TIA/thromboembolism 13,6% per year 7p - stroke risk 11,2% per year, risk of stroke/TIA/thromboembolism 15,7% per year 8p - stroke risk 10,8% per year, risk of stroke/TIA/thromboembolism 15,2% per year 9p - stroke risk 12,2% per year, risk of stroke/TIA/thromboembolism 17,4% per year
Do not use in patients with no diagnosis of atrial fibrillation.
[1] Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137(2):263-72. [2] Camm a J, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010 Oct;31(19):2369–429. [3] Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010 Dec;41(12):2731-8. [4] Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012 Jun;33(12):1500-10.
OBSERVATION.chadsvasc_score.v1, OBSERVATION.basic_demographic.v1, EVALUATION.cha2ds2_vasc_assessment.v1
